Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate Oxidation

Exclusion Criteria

• •1. Clinical diagnosis of Type 1 or 2 Diabetes Mellitus.
• •2. Active cardiovascular disease: participants who experienced a heart attack in the last year, or participants who are currently under regular control of a physician for a heart condition.
• •3. Weight gain or loss \> 5 kg in the last 3 months, ongoing weight-loss diet (hypocaloric diet) or use of weight loss agents.
• •4. Regular smoking and other regular nicotine use.
• •5. Anaemia.
• •6. Uncontrolled hypertension.
• •7. Clinically significant out of range values of serum levels of either alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) in the Investigator's opinion.
• •8. Unstable or rapidly progressing renal disease or estimated Glomerular Filtration Rate (eGFR) \<60 mL/min (Cockcroft-Gault formula).
• •9. Use of anti-coagulant treatment and other concomitant medication will be evaluated on a case to case basis with a general physician.
• •10. Use of medication such as oral glucocorticoids, anti-estrogens or other medications that are known to markedly influence insulin sensitivity.
• •11. Use of loop diuretics.
• •12. Intake of dietary supplements except multi-vitamins and minerals.
• •13. Alcohol consumption of \> 14 drinks per week for women and \> 21 drinks per week for men (1 drink = 35 cl beer, 14 cl wine or 4 cl hard liquor).
• •14. Known hypersensitivity to dapagliflozin or any of the excipients of the product.
• •15. For women only - currently pregnant (confirmed with positive pregnancy test) or breast-feeding.
• •16. Participation in another biomedical study within 1 month before the screening visit.
• •17. Any contraindication for MRI scanning.
• •18. Participants who do not want to be informed about unexpected medical findings, or do not wish that their physician be informed about coincidental findings, cannot participate in the study.